Characterizaton and Validation 2023

Current limitations & potential innovations in developing IND-enabling rAAV- & lentivirus-based gene therapy drug products

Cell & Gene Therapy Insights 2023; 9(11), 1449–1456

DOI: 10.18609/cgti.2023.189

Published: 6 December 2023
Rahul Kaushik

Abi Pinchbeck, Assistant Editor, Cell & Gene Therapy Insights, speaks to Rahul Kaushik, viral vector-based gene therapy expert, who compares recombinant AAVs and lentiviral vectors for in vivo and ex vivo gene therapy and discusses novel analytical tools in the space, including those to overcome purity analysis, immunogenicity toxicity, and re-dosing challenges